The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Target per user-provided UniProt context: UniProt accession P10361, protein name cellular tumor antigen p53 (tumor suppressor p53), gene Tp53 in Rattus norvegicus.
Verification against current literature: The retrieved literature consistently describes p53 as a conserved p53-family transcription factor with the expected domain architecture (transactivation regions, central sequence-specific DNA-binding domain, tetramerization/oligomerization domain, C-terminal regulatory region) and a stress-responsive tumor-suppressor role, matching the UniProt domain/family context (p53 family; p53 DNA-binding and tetramerization superfamily) (liu2024understandingthecomplexity pages 1-3, shen2023targetingthep53 pages 1-2, benitez2024p53geneticsand pages 3-4). Rat-relevant evidence explicitly refers to Rattus norvegicus and demonstrates Tp53-dependent regulation in rat-derived endothelial cells, anchoring that we are not conflating Tp53 with an unrelated gene symbol in another organism (bhagwani2023ap53tlr3axis pages 4-7).
Tp53 encodes p53, a sequence-specific DNA-binding transcription factor that acts as a central stress-response node and tumor suppressor (“guardian of the genome”) (wang2023targetingp53pathways pages 2-4, wang2023targetingp53pathways pages 1-2, shen2023targetingthep53 pages 1-2). Functionally, p53 binds p53 response elements in the genome and transcriptionally regulates gene programs that determine cell fate under stress, prominently including cell-cycle arrest, DNA repair, apoptosis, and senescence (wang2023targetingp53pathways pages 2-4, wang2023targetingp53pathways pages 1-2, shen2023targetingthep53 pages 1-2).
Because p53 is not an enzyme or transporter, its “primary function” in a functional-annotation sense is best defined as:
Recent expert reviews describe canonical p53 domain organization, which matches the expected family/domain context in UniProt:
A structurally explicit domain map (with residue boundaries, described for human p53 but used broadly for conserved p53 annotation) is provided by a 2023 review, including TAD-1 (1–39), TAD-2 (40–60), PRD (61–93), DBD (94–292), and the tetramerization region (OD, 323–355) (shen2023targetingthep53 pages 1-2).
The p53 pathway is often summarized as a stress → p53 stabilization/activation → transcriptional program → cell fate cascade, with negative feedback through MDM2.
A recent schematic of this pathway (kinases, MDM2/MDMX, and downstream outputs) is shown in Wang et al. 2023 (Figure 2) (wang2023targetingp53pathways media 8f681ea1).
Primary molecular function:
Representative downstream targets and outputs (canonical):
Recent reviews emphasize multi-layer regulation:
p53 functions predominantly as a nuclear transcription factor, with key non-nuclear roles:
Modern syntheses emphasize that p53 outputs are broader than the classic triad (arrest/apoptosis/senescence):
While many mechanistic reviews are species-general, direct rat evidence is available and is important for avoiding symbol ambiguity.
A 2023 iScience study provides explicit rat evidence in a pulmonary vascular context:
This rat evidence supports a functional annotation for rat Tp53 that includes not only canonical DNA-damage responses but also regulation of endothelial programs relevant to pulmonary vascular remodeling.
Two authoritative 2023–2024 reviews emphasize that p53 is best annotated as a context- and tissue-dependent transcriptional regulator, not a single fixed program:
A 2024 review focused on covalent modifications reiterates p53 activity as being heavily regulated via PTMs that affect tetramer assembly on DNA, stability (proteolysis vs accumulation), and transcriptional competence (grigoreva2024p53themultifaceted pages 2-4, grigoreva2024p53themultifaceted pages 1-2).
A 2024 mutation-focused review consolidates mechanistic categories useful for annotation (loss-of-function, dominant-negative, gain-of-function) and provides quantitative mutation patterns (see Section 6) (tornesello2024tp53mutationsin pages 1-2, tornesello2024tp53mutationsin pages 2-3).
Because many tumors inactivate p53 by mutation or by overactive negative regulators, a major clinical strategy for TP53-wild-type disease is to inhibit the p53–MDM2 interaction and thereby restore endogenous p53 activity (wang2023targetingp53pathways pages 2-4, gollner2024discoveryandcharacterization pages 1-2).
In a 2024 ESMO Open phase I study of alrizomadlin/APG-115 in advanced solid tumors:
These results exemplify both the promise and the on-target hematologic toxicity profile common to MDM2–p53 antagonists.
ClinicalTrials.gov records show continuing development and deployment of MDM2 inhibitors:
Rat models can also be used to test p53 activation as a mechanism-based intervention. In the rat endothelial clonal-expansion context described above, Nutlin-3a (MDM2 inhibitor) suppressed clonogenic expansion and modulated downstream gene expression, showing a mechanistic bridge between pathway pharmacology and in vivo vascular pathology models (bhagwani2023ap53tlr3axis pages 4-7, bhagwani2023ap53tlr3axis pages 1-2).
A consistent theme in 2023–2024 expert syntheses is that p53 should be annotated as a multi-layer regulated, context-specific transcriptional system:
A 2024 review provides several widely used quantitative anchors:
These statistics contextualize why p53 pathway biology is central to functional annotation and therapeutic development.
From the 2024 APG-115 phase I study (see above): ORR 10% overall; stable disease 50%; median PFS 6.1 months; and improved PFS in TP53 wild-type vs mutant (P < 0.001) (zhang2024afirstinhumanphase pages 1-2). These data represent real-world quantitative outcomes for p53 pathway reactivation.
A pathway schematic summarizing upstream stresses (ATM/ATR/Chk signaling), negative regulation (MDM2/MDMX), and downstream p53-mediated outcomes (cell-cycle arrest, DNA repair, apoptosis, metabolism, autophagy) is available from Wang et al. 2023 (Figure 2) (wang2023targetingp53pathways media 8f681ea1).
Tp53 (rat; UniProt P10361) encodes p53, a conserved p53-family, sequence-specific DNA-binding transcription factor that forms tetramers and integrates diverse cellular stress signals to regulate transcriptional programs governing cell-cycle arrest, DNA repair, apoptosis, senescence, and additional processes such as metabolism, autophagy and ferroptosis-related pathways. p53’s activity is primarily controlled by MDM2/MDMX-mediated ubiquitination and extensive PTMs that tune stability, localization, and promoter/enhancer selectivity. p53 acts mainly in the nucleus but also exerts cytoplasmic/mitochondrial pro-apoptotic functions. In Rattus norvegicus, Tp53 has direct experimental support in endothelial biology, including conserved p53 response elements in the rat TLR3 gene and Tp53-dependent regulation of Tlr3/Id1 and angiogenic behavior in rat lung endothelial clones.
| Category | Key points | Key recent sources |
|---|---|---|
| Identity/Domain | • Verified target context: rat Tp53 encodes cellular tumor antigen p53, a conserved p53-family transcription factor consistent with UniProt P10361. • Conserved domain architecture includes N-terminal transactivation regions, proline-rich region, central DNA-binding domain, oligomerization/tetramerization domain, and C-terminal regulatory region. • Functional p53 acts as a tetramer; tetramerization is required for efficient DNA binding and full transactivation. |
• Liu et al., 2024, Cancer Cell — https://doi.org/10.1016/j.ccell.2024.04.009 (liu2024understandingthecomplexity pages 1-3) • Shen et al., 2023, MedComm — https://doi.org/10.1002/mco2.288 (shen2023targetingthep53 pages 1-2) • Benitez et al., 2024, Biomedicines — https://doi.org/10.3390/biomedicines12071453 (benitez2024p53geneticsand pages 3-4) |
| Molecular function | • Primary function is sequence-specific DNA-binding transcription factor activity, activating or repressing stress-response genes. • Canonical outputs include cell-cycle arrest, DNA repair, apoptosis, and senescence. • Representative downstream effectors include CDKN1A/p21, BAX, PUMA, and NOXA; p53 can also promote apoptosis through non-transcriptional mitochondrial actions. |
• Wang et al., 2023, Signal Transduction and Targeted Therapy — https://doi.org/10.1038/s41392-023-01347-1 (wang2023targetingp53pathways pages 2-4, wang2023targetingp53pathways pages 1-2) • Grigoreva et al., 2024, Pharmaceuticals — https://doi.org/10.3390/ph17121682 (grigoreva2024p53themultifaceted pages 2-4, grigoreva2024p53themultifaceted pages 1-2) • Tornesello, 2024, Int J Mol Med — https://doi.org/10.3892/ijmm.2024.5448 (tornesello2024tp53mutationsin pages 2-3, tornesello2024tp53mutationsin pages 1-2) |
| Regulation | • Under basal conditions, p53 abundance is kept low mainly by MDM2/MDMX-mediated ubiquitination and proteasomal turnover. • Stress signals such as DNA damage activate ATM/ATR/Chk pathways, promoting post-translational modifications that stabilize and activate p53. • p53 induces MDM2 transcription, creating a classic negative-feedback loop; PTMs also influence tetramer assembly and promoter selectivity. |
• Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (wang2023targetingp53pathways pages 2-4, wang2023targetingp53pathways pages 1-2) • Grigoreva et al., 2024 — https://doi.org/10.3390/ph17121682 (grigoreva2024p53themultifaceted pages 2-4, grigoreva2024p53themultifaceted pages 1-2) • Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pasadas2024exploringtheimpact pages 42-46) |
| Localization | • p53 functions predominantly in the nucleus, where stress-stabilized tetramers bind p53 response elements in promoters/enhancers. • It is also present in the cytoplasm and can relocalize to mitochondria for transcription-independent apoptotic signaling. • MDM2-mediated ubiquitination contributes to nuclear export and degradation. |
• Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (wang2023targetingp53pathways pages 1-2) • Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pasadas2024exploringtheimpact pages 42-46) • Grigoreva et al., 2024 — https://doi.org/10.3390/ph17121682 (grigoreva2024p53themultifaceted pages 1-2) |
| Pathways/Processes | • Core pathway role: DNA damage response linking genotoxic or oncogenic stress to transcriptional reprogramming. • Major biological processes include G1/G2 checkpoint control, DNA repair facilitation, apoptosis, senescence, metabolism, autophagy, and ferroptosis-related regulation. • p53 pathway logic is summarized in recent pathway schematics integrating ATM/ATR, MDM2/MDMX, and downstream targets. |
• Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (wang2023targetingp53pathways pages 2-4, wang2023targetingp53pathways pages 1-2, wang2023targetingp53pathways media 8f681ea1) • Pant et al., 2023, Cell Death Differ — https://doi.org/10.1038/s41418-023-01123-2 (benitez2024p53geneticsand pages 3-4) • Liu et al., 2024 — https://doi.org/10.1016/j.ccell.2024.04.009 (liu2024understandingthecomplexity pages 1-3) |
| Rat-specific evidence | • Direct rat-relevant evidence exists for a p53–TLR3 axis: multiple p53 consensus elements were identified in the TLR3 gene across species including Rattus norvegicus. • In rat lung CD117+ endothelial cells, clonal expansion reduced Tp53 and Tlr3 expression; Nutlin-3a blocked clonogenic expansion. • Rat Tp53 silencing lowered Tlr3 and Id1 mRNA and increased angiogenic behavior, linking rat Tp53 to pulmonary vascular homeostasis. |
• Bhagwani et al., 2023, iScience — https://doi.org/10.1016/j.isci.2023.105935 (bhagwani2023ap53tlr3axis pages 4-7, bhagwani2023ap53tlr3axis pages 21-22, bhagwani2023ap53tlr3axis pages 1-2, bhagwani2023ap53tlr3axis pages 22-24) |
| Disease relevance/statistics | • TP53 is the most frequently mutated gene in human cancer; mutation/inactivation occurs in ~50% of cancers, with frequencies >50% in at least 20 tumor types. • >80% of TP53 alterations are missense mutations, concentrated in the DNA-binding domain; ~30% of missense mutations cluster at hotspot codons. • In tumors with one mutant TP53 allele, >90% reportedly lose the second allele by LOH/deletion/mutation, underscoring tumor-suppressor function. |
• Tornesello, 2024 — https://doi.org/10.3892/ijmm.2024.5448 (tornesello2024tp53mutationsin pages 2-3, tornesello2024tp53mutationsin pages 1-2) • Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (wang2023targetingp53pathways pages 1-2) • Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pasadas2024exploringtheimpact pages 42-46, pasadas2024exploringtheimpact pages 38-42) |
| Therapies/applications | • Current translational strategy for TP53-wild-type tumors is pharmacologic MDM2–p53 inhibition to reactivate endogenous p53. • In the 2024 first-in-human alrizomadlin (APG-115) trial, MTD 150 mg, RP2D 100 mg; grade 3–4 TRAEs included thrombocytopenia and neutropenia, with pharmacodynamic evidence of p53 activation. • Among 20 evaluable patients, ORR 10%, stable disease 50%, median PFS 6.1 months; in MDM2-amplified/TP53-wild-type tumors, ORR 25% (2/8) and DCR 100% (8/8); several ongoing APG-115 and brigimadlin trials support real-world clinical implementation. |
• Zhang et al., 2024, ESMO Open — https://doi.org/10.1016/j.esmoop.2024.103636 (zhang2024afirstinhumanphase pages 2-3, zhang2024afirstinhumanphase pages 1-2) • Gollner et al., 2024, Mol Cancer Ther — https://doi.org/10.1158/1535-7163.mct-23-0783 (gollner2024discoveryandcharacterization pages 1-2, gollner2024discoveryandcharacterization pages 14-14) • Clinical trials: NCT02935907, NCT03611868, NCT03449381, NCT05218499 |
Table: This table condenses the most relevant functional-annotation evidence for rat Tp53 (UniProt P10361), spanning identity, molecular function, regulation, localization, pathways, rat-specific experiments, disease statistics, and therapeutic applications. It is designed to support a comprehensive narrative report with recent, citable sources.
References
(liu2024understandingthecomplexity pages 1-3): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 501 citations and is from a highest quality peer-reviewed journal.
(shen2023targetingthep53 pages 1-2): Jinze Shen, Qurui Wang, Yunan Mao, Wei Gao, and Shiwei Duan. Targeting the p53 signaling pathway in cancers: molecular mechanisms and clinical studies. MedComm, May 2023. URL: https://doi.org/10.1002/mco2.288, doi:10.1002/mco2.288. This article has 64 citations.
(benitez2024p53geneticsand pages 3-4): Dixan A. Benitez, Guadalupe Cumplido-Laso, Marcos Olivera-Gómez, Nuria Del Valle-Del Pino, Alba Díaz-Pizarro, Sonia Mulero-Navarro, Angel Román-García, and Jose Maria Carvajal-Gonzalez. P53 genetics and biology in lung carcinomas: insights, implications and clinical applications. Biomedicines, 12:1453, Jun 2024. URL: https://doi.org/10.3390/biomedicines12071453, doi:10.3390/biomedicines12071453. This article has 9 citations.
(bhagwani2023ap53tlr3axis pages 4-7): Aneel R. Bhagwani, Mehboob Ali, Bryce Piper, Mingjun Liu, Jaylen Hudson, Neil Kelly, Srimathi Bogamuwa, Hu Yang, James D. Londino, Joseph S. Bednash, Daniela Farkas, Rama K. Mallampalli, Mark R. Nicolls, John J. Ryan, A.A. Roger Thompson, Stephen Y. Chan, Delphine Gomez, Elena A. Goncharova, and Laszlo Farkas. A p53-tlr3 axis ameliorates pulmonary hypertension by inducing bmpr2 via irf3. iScience, 26:105935, Feb 2023. URL: https://doi.org/10.1016/j.isci.2023.105935, doi:10.1016/j.isci.2023.105935. This article has 17 citations and is from a peer-reviewed journal.
(wang2023targetingp53pathways pages 2-4): Haolan Wang, M. Guo, Hudie Wei, and Yongheng Chen. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduction and Targeted Therapy, Mar 2023. URL: https://doi.org/10.1038/s41392-023-01347-1, doi:10.1038/s41392-023-01347-1. This article has 1111 citations and is from a peer-reviewed journal.
(wang2023targetingp53pathways pages 1-2): Haolan Wang, M. Guo, Hudie Wei, and Yongheng Chen. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduction and Targeted Therapy, Mar 2023. URL: https://doi.org/10.1038/s41392-023-01347-1, doi:10.1038/s41392-023-01347-1. This article has 1111 citations and is from a peer-reviewed journal.
(grigoreva2024p53themultifaceted pages 1-2): Tatiana A. Grigoreva, Angelina A. Romanova, Vyacheslav G. Tribulovich, Nikolay B. Pestov, Ruslan A. Oganov, Diana K. Kovaleva, Tatyana V. Korneenko, and Nickolai A. Barlev. P53: the multifaceted roles of covalent modifications in cancer. Pharmaceuticals, 17:1682, Dec 2024. URL: https://doi.org/10.3390/ph17121682, doi:10.3390/ph17121682. This article has 13 citations.
(pasadas2024exploringtheimpact pages 42-46): Mónica Cabrera Pasadas. Exploring the impact of p53 activation on spatio-temporal genome topology. ArXiv, 2024. URL: https://doi.org/10.5821/dissertation-2117-422069, doi:10.5821/dissertation-2117-422069. This article has 0 citations.
(grigoreva2024p53themultifaceted pages 2-4): Tatiana A. Grigoreva, Angelina A. Romanova, Vyacheslav G. Tribulovich, Nikolay B. Pestov, Ruslan A. Oganov, Diana K. Kovaleva, Tatyana V. Korneenko, and Nickolai A. Barlev. P53: the multifaceted roles of covalent modifications in cancer. Pharmaceuticals, 17:1682, Dec 2024. URL: https://doi.org/10.3390/ph17121682, doi:10.3390/ph17121682. This article has 13 citations.
(wang2023targetingp53pathways media 8f681ea1): Haolan Wang, M. Guo, Hudie Wei, and Yongheng Chen. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduction and Targeted Therapy, Mar 2023. URL: https://doi.org/10.1038/s41392-023-01347-1, doi:10.1038/s41392-023-01347-1. This article has 1111 citations and is from a peer-reviewed journal.
(pawlicka2024proteogenomicplatformsestablishing pages 25-29): Kamila Pawlicka. Proteogenomic platforms establishing personalized and precision neoantigen therapeutics in cancer. Jul 2024. URL: https://doi.org/10.7488/era/4721, doi:10.7488/era/4721. This article has 0 citations.
(tornesello2024tp53mutationsin pages 1-2): Maria Tornesello. Tp53 mutations in cancer: molecular features and therapeutic opportunities (review). International Journal of Molecular Medicine, Oct 2024. URL: https://doi.org/10.3892/ijmm.2024.5448, doi:10.3892/ijmm.2024.5448. This article has 83 citations and is from a peer-reviewed journal.
(liu2024understandingthecomplexity pages 3-4): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 501 citations and is from a highest quality peer-reviewed journal.
(pant2023tissuespecificityand pages 2-3): Vinod Pant, Chang Sun, and Guillermina Lozano. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death & Differentiation, 30:897-905, Feb 2023. URL: https://doi.org/10.1038/s41418-023-01123-2, doi:10.1038/s41418-023-01123-2. This article has 24 citations and is from a domain leading peer-reviewed journal.
(liu2024understandingthecomplexity pages 6-8): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 501 citations and is from a highest quality peer-reviewed journal.
(liu2024understandingthecomplexity pages 16-18): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 501 citations and is from a highest quality peer-reviewed journal.
(pant2023tissuespecificityand pages 1-2): Vinod Pant, Chang Sun, and Guillermina Lozano. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death & Differentiation, 30:897-905, Feb 2023. URL: https://doi.org/10.1038/s41418-023-01123-2, doi:10.1038/s41418-023-01123-2. This article has 24 citations and is from a domain leading peer-reviewed journal.
(bhagwani2023ap53tlr3axis pages 1-2): Aneel R. Bhagwani, Mehboob Ali, Bryce Piper, Mingjun Liu, Jaylen Hudson, Neil Kelly, Srimathi Bogamuwa, Hu Yang, James D. Londino, Joseph S. Bednash, Daniela Farkas, Rama K. Mallampalli, Mark R. Nicolls, John J. Ryan, A.A. Roger Thompson, Stephen Y. Chan, Delphine Gomez, Elena A. Goncharova, and Laszlo Farkas. A p53-tlr3 axis ameliorates pulmonary hypertension by inducing bmpr2 via irf3. iScience, 26:105935, Feb 2023. URL: https://doi.org/10.1016/j.isci.2023.105935, doi:10.1016/j.isci.2023.105935. This article has 17 citations and is from a peer-reviewed journal.
(tornesello2024tp53mutationsin pages 2-3): Maria Tornesello. Tp53 mutations in cancer: molecular features and therapeutic opportunities (review). International Journal of Molecular Medicine, Oct 2024. URL: https://doi.org/10.3892/ijmm.2024.5448, doi:10.3892/ijmm.2024.5448. This article has 83 citations and is from a peer-reviewed journal.
(gollner2024discoveryandcharacterization pages 1-2): Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Jürgen Ramharter, Rolf Grempler, Jens Quant, Jörg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B. McConnell, Norbert Kraut, and Patrizia Sini. Discovery and characterization of brigimadlin, a novel and highly potent mdm2–p53 antagonist suitable for intermittent dose schedules. Molecular Cancer Therapeutics, 23:1689-1702, Sep 2024. URL: https://doi.org/10.1158/1535-7163.mct-23-0783, doi:10.1158/1535-7163.mct-23-0783. This article has 14 citations and is from a peer-reviewed journal.
(zhang2024afirstinhumanphase pages 1-2): X. Zhang, X. Wen, R. Peng, Q. Pan, D. Weng, Y. Ma, Y. Zhang, J. Yang, L. Men, H. Wang, E. Liang, C. Wang, D. Yang, L. Zhang, Y. Zhai, Prof. Xing Zhang, and Prof. Li Zhang. A first-in-human phase i study of a novel mdm2/p53 inhibitor alrizomadlin in advanced solid tumors. ESMO Open, 9:103636, Aug 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103636, doi:10.1016/j.esmoop.2024.103636. This article has 34 citations and is from a domain leading peer-reviewed journal.
(NCT02935907 chunk 1): APG-115 in Patients With Advanced Solid Tumors or Lymphomas. Ascentage Pharma Group Inc.. 2016. ClinicalTrials.gov Identifier: NCT02935907
(NCT03449381 chunk 1): This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors). Boehringer Ingelheim. 2018. ClinicalTrials.gov Identifier: NCT03449381
(liu2024understandingthecomplexity pages 11-13): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 501 citations and is from a highest quality peer-reviewed journal.
(bhagwani2023ap53tlr3axis pages 21-22): Aneel R. Bhagwani, Mehboob Ali, Bryce Piper, Mingjun Liu, Jaylen Hudson, Neil Kelly, Srimathi Bogamuwa, Hu Yang, James D. Londino, Joseph S. Bednash, Daniela Farkas, Rama K. Mallampalli, Mark R. Nicolls, John J. Ryan, A.A. Roger Thompson, Stephen Y. Chan, Delphine Gomez, Elena A. Goncharova, and Laszlo Farkas. A p53-tlr3 axis ameliorates pulmonary hypertension by inducing bmpr2 via irf3. iScience, 26:105935, Feb 2023. URL: https://doi.org/10.1016/j.isci.2023.105935, doi:10.1016/j.isci.2023.105935. This article has 17 citations and is from a peer-reviewed journal.
(bhagwani2023ap53tlr3axis pages 22-24): Aneel R. Bhagwani, Mehboob Ali, Bryce Piper, Mingjun Liu, Jaylen Hudson, Neil Kelly, Srimathi Bogamuwa, Hu Yang, James D. Londino, Joseph S. Bednash, Daniela Farkas, Rama K. Mallampalli, Mark R. Nicolls, John J. Ryan, A.A. Roger Thompson, Stephen Y. Chan, Delphine Gomez, Elena A. Goncharova, and Laszlo Farkas. A p53-tlr3 axis ameliorates pulmonary hypertension by inducing bmpr2 via irf3. iScience, 26:105935, Feb 2023. URL: https://doi.org/10.1016/j.isci.2023.105935, doi:10.1016/j.isci.2023.105935. This article has 17 citations and is from a peer-reviewed journal.
(pasadas2024exploringtheimpact pages 38-42): Mónica Cabrera Pasadas. Exploring the impact of p53 activation on spatio-temporal genome topology. ArXiv, 2024. URL: https://doi.org/10.5821/dissertation-2117-422069, doi:10.5821/dissertation-2117-422069. This article has 0 citations.
(zhang2024afirstinhumanphase pages 2-3): X. Zhang, X. Wen, R. Peng, Q. Pan, D. Weng, Y. Ma, Y. Zhang, J. Yang, L. Men, H. Wang, E. Liang, C. Wang, D. Yang, L. Zhang, Y. Zhai, Prof. Xing Zhang, and Prof. Li Zhang. A first-in-human phase i study of a novel mdm2/p53 inhibitor alrizomadlin in advanced solid tumors. ESMO Open, 9:103636, Aug 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103636, doi:10.1016/j.esmoop.2024.103636. This article has 34 citations and is from a domain leading peer-reviewed journal.
(gollner2024discoveryandcharacterization pages 14-14): Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Jürgen Ramharter, Rolf Grempler, Jens Quant, Jörg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B. McConnell, Norbert Kraut, and Patrizia Sini. Discovery and characterization of brigimadlin, a novel and highly potent mdm2–p53 antagonist suitable for intermittent dose schedules. Molecular Cancer Therapeutics, 23:1689-1702, Sep 2024. URL: https://doi.org/10.1158/1535-7163.mct-23-0783, doi:10.1158/1535-7163.mct-23-0783. This article has 14 citations and is from a peer-reviewed journal.